Novartis' new chronic myelogenous leukemia drug Scemblix is entering prescription rights in general hospitals.

According to related industries, Novartis Korea's Ph+CML Philadelphia chromosome-positive chronic myeloid leukemia treatment drug Scemblix has been approved by the Drug Committee (DC) of medical institutions such as Seoul St. Mary's Hospital and Seoul Asan Hospital, as well as Kyungpook National University Hospital and Uijeongbu Eulji Hospital. As the insurance benefits process is currently underway, the prescription environment is being created quickly. Scemblix was approved in Korea in June last year for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia in the ch